Back
Compare AU
Compare DRUG vs. CNEW
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the VanEck China New Economy ETF (CNEW). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | CNEW | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 65 |
Median incremental investment | $735.27 | $807.64 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,024.96 | $2,123.19 |
Average age group | > 35 | > 35 |
Key Summary
DRUG | CNEW | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | CNEW.AX was created on 2018-11-08 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. CNEW.AX gives investors a portfolio of the most fundamentally sound companies in China having the best growth prospects in sectors making up the New Economy, namely technology, health care, consumer staples and consumer discretionary. CNEW.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index. |
Top 3 holdings | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) | Kuaijishan Shaoxing Rice Wine Co Ltd Class A (2.16 %) GemPharmatech Co Ltd Class A (1.73 %) Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A (1.47 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Information Technology (33.78 %) Health Care (27.01 %) Consumer Discretionary (20.43 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | China (100.00 %) |
Management fee | 0.57 % | 0.95 % |
Key Summary
DRUG | CNEW | |
|---|---|---|
Issuer | BetaShares | VanEck |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | CSI MarketGrader China New Economy Index - CNY |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.95 % |
Price | $9.04 | $7.61 |
Size | $174.867 million | $95.902 million |
10Y return | 90.32 % | N/A |
Annual distribution yield (5Y) | 1.82 % | 1.38 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 09/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | CNEW | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 74 | 65 |
Median incremental investment | $735.27 | $807.64 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,024.96 | $2,123.19 |
Average age group | > 35 | > 35 |
Pros and Cons
DRUG | CNEW | |
|---|---|---|
Pros |
| |
Cons |
|
DRUG | CNEW |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |